Table 2.
Effect of somatic mutations on outcomes after allogeneic hematopoietic cell transplantation
| Gene mutation | Effect on outcomes |
|---|---|
| TP53 | Shorter OS13,37-41 |
| Higher RR,13,37-39 especially if complex karyotype present38 | |
| RAS pathway (including NRAS and CBL among others) | Shorter OS13,39 (only in MDS/MPN subtypes)38 |
| Higher RR after non-myeloablative conditioning13 | |
| Higher RR for CBL38 | |
| Higher NRM for NRAS38 | |
| Higher RR for NRAS39 | |
| JAK2 | Shorter OS13 |
| Higher NRM13 | |
| ASXL1 | Shorter OS37 |
| Higher RR13,37 | |
| DNMT3A | Higher RR38 |
| Lower NRM38 | |
| Shorter OS41 | |
| RUNX1 | Shorter OS37 |
| Higher RR37 | |
| IDH2 | Shorter OS39,40 |
| PPM1D (p53 regulator) | Shorter OS and more common in therapy-related MDS13 |
| SBDS | Shorter OS in young adults and associated with TP53 mutations13 |
| U2AF1 | Shorter OS39 |
| EZH2 | Higher RR39 |
| TET2 | Shorter OS41 |
MPN, myeloproliferative neoplasm; NRM, nonrelapse mortality; RR, relapse risk.